Galantamine is a reversible, competitive acetylcholinesterase inhibitor used primarily in the treatment of mild to moderate Alzheimer’s disease and other forms of dementia, where it helps improve cognition by increasing the levels of acetylcholine in the brain. It is a natural alkaloid originally isolated from plants in the Amaryllidaceae family, including the snowdrop (Galanthus species), from which it derives its name, and also from related species such as daffodils. Although its traditional use dates back to early ethnobotanical observations in Eastern Europe, galantamine was scientifically identified and studied in the mid-20th century, with its therapeutic potential for memory disorders becoming more established in the 1980s and 1990s. It was later developed into a pharmaceutical product and approved for clinical use in several countries for Alzheimer’s disease management, gaining wider acceptance in modern neurology due to its dual mechanism of acetylcholinesterase inhibition and nicotinic receptor modulation.
BRAND NAMES
Galantamine is marketed under the brand names Razadyne and Razadyne ER in the United States. It is used for the treatment of mild to moderate Alzheimer’s disease and other forms of dementia. It has also been known under the brand name Reminyl, although this name is less commonly used now. In addition, galantamine is available in generic formulations.
MECHANISM OF ACTION
Galantamine is a cholinesterase inhibitor used in the treatment of mild to moderate Alzheimer’s disease and is distinguished by a dual mechanism of action. It reversibly inhibits the enzyme acetylcholinesterase thereby increasing acetylcholine levels in the brain, and also acts as an allosteric modulator of nicotinic receptors, enhancing cholinergic neurotransmission.
PHARMACOKINETICS
Absorption: Rapidly absorbed after administration, with peak plasma concentrations (Cmax) reached in about 1 hour for immediate-release formulations and around 4 hours for extended-release forms. Food does not significantly affect the overall extent of absorption, although it may lower Cmax.
Distribution: Exhibits low plasma protein binding (approximately 18%–33%) and can readily cross the blood-brain barrier.
Metabolism: Mainly metabolized in the liver via CYP2D6 and CYP3A4 enzymes, producing metabolites such as norgalantamine and glucuronide conjugates.
Elimination: Has a terminal elimination half-life of approximately 7–8 hours.
PHARMACODYNAMICS
Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and an allosteric modulator of nicotinic acetylcholine receptors used in the treatment of Alzheimer’s disease. It improves cholinergic activity by inhibiting the breakdown of acetylcholine and enhancing its receptor binding, which helps support cognitive function.
ADMINISTRATION
Galantamine is administered orally in the form of tablets or oral solution and is available in both immediate-release and extended-release (ER) formulations. The immediate-release form is usually taken twice daily, while the ER formulation is taken once daily.
DOSAGE AND STRENGTH
Galantamine is available in multiple strengths depending on the formulation. Immediate-release tablets are commonly available in 4 mg, 8 mg, and 12 mg strengths, while the extended-release (ER) capsules are typically available in 8 mg, 16 mg, and 24 mg strengths. The dosage is individualized and usually started at a low dose, with gradual titration based on tolerance and clinical response in patients with Alzheimer’s disease.
DRUG INTERACTIONS
Galantamine is associated with a large number of drug interactions, including several that are clinically significant. These interactions mainly involve agents that affect heart rate or enhance cholinergic activity, which can increase side effects such as nausea and vomiting.
FOOD INTERACTIONS
Galantamine should be taken with food, preferably during morning and evening meals, along with plenty of water to help minimize gastrointestinal side effects such as nausea, vomiting, and diarrhea. Caution is advised with grapefruit products, including fruit, juice, and supplements, as they may increase the drug’s blood concentration.
CONTRAINDICATIONS
Galantamine is contraindicated in individuals with a known hypersensitivity to the drug, as well as in patients with severe renal impairment (creatinine clearance < 9 mL/min) and severe hepatic impairment (Child-Pugh score > 9). In general, it is not recommended for use in patients with significant kidney or liver dysfunction.
SIDE EFFECTS
Galantamine commonly causes gastrointestinal side effects such as nausea, vomiting, diarrhea, and loss of appetite, as well as dizziness and headache. These effects can often be minimized by taking the medication with food and gradually increasing the dose through slow titration. Rare but serious adverse effects include fainting, bradycardia (slow heart rate), severe skin reactions, and peptic ulcers.
OVER DOSE
Overdose may lead to exaggerated cholinergic effects due to excessive acetylcholine accumulation. Symptoms can include severe nausea, vomiting, diarrhea, abdominal cramps, increased salivation, sweating, bradycardia (slow heart rate), hypotension, muscle weakness, and, in severe cases, respiratory depression or collapse. Management is mainly supportive, with close monitoring of vital signs, and treatment may include the use of anticholinergic agents such as atropine under medical supervision.
TOXICITY
Galantamine toxicity, also known as a cholinergic crisis, results from excessive accumulation of acetylcholine in the body. This can lead to symptoms such as severe nausea, vomiting, diarrhea, bradycardia (slow heart rate), hypotension, respiratory depression, and seizures. Although it is a reversible cholinesterase inhibitor used in the treatment of Alzheimer’s disease, severe overdose can be life-threatening and may cause death due to respiratory failure.
